Oragenics, Inc.

Equities

OGEN

US6840235005

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:10:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.01 ^USD	-1.94%		-4.72%	-82.05%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Mar. 29	Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

April 17, 2023 at 05:29 pm EDT

Oragenics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 14.29 million compared to USD 15.71 million a year ago. Basic loss per share from continuing operations was USD 7.11 compared to USD 8.09 a year ago.

Latest news about Oragenics, Inc.

North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	Mar. 18	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	Mar. 05	CI
Top Midday Decliners	Feb. 28	MT
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	Feb. 13	MT
Oragenics, Inc. Announces Leadership Transition	Feb. 12	CI
Oragenics, Inc. Announces CEO Changes	Feb. 12	CI
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	Feb. 05	CI
Oragenics, Inc. Announces Management Changes	Dec. 29	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	Dec. 27	CI
Oragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Oragenics Announces Directorate Appointments	23-10-18	CI
Oragenics, Inc. Announces Board Appointments	23-10-05	CI
Oragenics Signs Cash, Share Deal to Acquire Odyssey Health's Neurological Drug Technology Pipeline	23-10-05	MT
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	23-10-04	CI
North American Morning Briefing : Stock Futures, Yields Rise After Shutdown Averted	23-10-02	DJ
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Oragenics, Inc. announced that it has received $0.85 million in funding	23-08-07	CI
Oragenics, Inc. announced a financing transaction	23-08-03	CI
Oragenics to Develop Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05	MT
Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05	CI
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI

Chart Oragenics, Inc.

Duration

Period

More charts

Company Profile

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ORAGENICS, INC.	-82.05%	4.53M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.72%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.49%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

Oragenics, Inc.

Equities

OGEN

US6840235005

Biotechnology & Medical Research

Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

Latest news about Oragenics, Inc.

Chart Oragenics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs